NCT01995370 - Cilostazol Stroke Prevention Study for Antiplatelet Combination | Biotech Hunter

Enrollment

1,884

Participants

Timeline

Start Date

December 13, 2013

Primary Completion Date

December 7, 2018

Study Completion Date

December 7, 2018

Conditions

Noncardioembolic Cerebral Infarction

Interventions

DRUG

aspirin

Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.

DRUG

clopidogrel

Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.

DRUG

cilostazol

Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.

Trial Locations (1)

565-8565

Japan Cardiovascular Research Foundation, Osaka